Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18948773 | PREPARATION METHOD OF MESENCHYMAL STEM CELL (MSC) AND APPLICATION THEREOF IN KNEE PRODUCT | November 2024 | August 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18436632 | HUMAN FIBROLAMELLAR HEPATOCELLULAR CARCINOMAS (hFL-HCCS) | February 2024 | December 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18480956 | METHOD OF PRODUCING CANCER STEM CELLS | October 2023 | September 2025 | Abandon | 24 | 2 | 1 | No | No |
| 18459692 | CARDIAC STEM CELLS FOR CARDIAC REPAIR | September 2023 | May 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18240744 | CONTINUOUSLY BIOPRINTED MULTILAYER TISSUE STRUCTURE | August 2023 | October 2025 | Allow | 26 | 2 | 1 | No | No |
| 18129398 | Post-Natal Transplantation Of Factor VIII-Expressing Cells For Treatment of Hemophilia | March 2023 | January 2026 | Allow | 34 | 2 | 0 | Yes | No |
| 18192682 | GRAFT SCAFFOLD FOR CARTILAGE REPAIR AND PROCESS FOR MAKING SAME | March 2023 | April 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18190783 | BONE MARROW DERIVED NEUROKININ-1 RECEPTOR POSITIVE (NK1R+) MESENCHYMAL STEM CELLS FOR THERAPEUTIC APPLICATIONS | March 2023 | October 2025 | Abandon | 31 | 1 | 1 | No | No |
| 18123920 | METHODS FOR THE TREATMENT OF BETA-THALASSEMIA | March 2023 | March 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18175154 | CARDIAC STEM CELLS FOR CARDIAC REPAIR | February 2023 | November 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 18112095 | METHOD OF CULTURING NK CELLS AND KITS CONTAINING MEDIUM ADDITIONS | February 2023 | February 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18041153 | USES OF MSC IN IMPROVING THROMBOTIC COMPLICATIONS IN COVID-19 PNEUMONIA | February 2023 | March 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18104924 | GENERATION OF A MESENCHYMAL STROMAL CELL BANK FROM THE POOLED MONONUCLEAR CELLS OF MULTIPLE BONE MARROW DONORS | February 2023 | November 2025 | Allow | 33 | 2 | 1 | No | No |
| 18005051 | METHOD OF ENCAPSULATION OF AN ACTIVE PROTEIN USING ELECTRODEPOSITION TECHNIQUES, AN IMMUNOMODULATING COMPOSITION CONTAINING THE ACTIVE PROTEIN AND A POLYMER, AND ITS USE FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATOPIC DERMATITIS IN HUMANS | January 2023 | March 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18147269 | COMBINATION THERAPY COMPRISING A COMPOSITION OF MESENCHYMAL STROMAL CELLS AND HYALURONIC ACID FOR USE IN TREATMENT OF OSTEOARTHRITIS | December 2022 | February 2026 | Allow | 38 | 1 | 0 | Yes | No |
| 18146142 | METHOD FOR EXPANSION OF DOUBLE NEGATIVE REGULATORY T CELLS | December 2022 | March 2026 | Allow | 38 | 1 | 0 | Yes | No |
| 18084206 | C-KIT-POSITIVE BONE MARROW CELLS AND USES THEREOF | December 2022 | January 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18080373 | CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS | December 2022 | July 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18009605 | METHODS AND COMPOSITIONS FOR TREATING CORONAVIRUS INFECTIOUS DISEASE | December 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18008911 | CELL/GENE THERAPIES TARGETING MAGE-A4 PEPTIDE | December 2022 | March 2026 | Allow | 39 | 1 | 0 | No | No |
| 17927940 | USE OF MRNAS ENCODING OX40L, IL-23 AND IL-36GAMMA FOR TREATING CANCER | November 2022 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17927335 | CELL-DERIVED VESICLE RICH IN PROTEIN HOMEOSTASIS REGULATORS AND METHOD OF PREPARING SAME | November 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18057487 | TREATMENT OF PREMATURE BIRTH COMPLICATIONS | November 2022 | December 2024 | Abandon | 25 | 0 | 1 | No | No |
| 18053847 | CELL SHEET HAVING FIBROSIS INHIBITORY ACTION | November 2022 | January 2025 | Abandon | 26 | 1 | 0 | No | No |
| 17981736 | METHOD FOR ENHANCING EXPRESSION OF INSULIN LIKE GROWTH FACTOR 1 RECEPTOR IN UMBILICAL CORD MESENCHYMAL STEM CELL EXPRESSING IGF1R AND METHOD FOR OBTAINING MULTIPOTENT UMBILICAL CORD MESENCHYMAL STEM CELL | November 2022 | October 2024 | Allow | 23 | 1 | 1 | No | No |
| 17923871 | METHOD FOR PRODUCING EXTRACELLULAR VESICLES COMPRISING FETUS-DERIVED PRIMAL IMMUNOGLOBULIN | November 2022 | July 2024 | Allow | 20 | 2 | 1 | Yes | No |
| 18045137 | METHODS FOR CULTURING CELLS AND KITS AND APPARATUS FOR SAME | October 2022 | September 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17820473 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | August 2022 | February 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17904433 | AAV CAPSID-PROMOTER INTERACTIONS AND CELL SELECTIVE GENE EXPRESSION | August 2022 | February 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17817757 | METHODS FOR DIFFERENTIATING MESENCHYMAL STEM CELLS | August 2022 | December 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17873344 | Lymphocyte-Based Morphometric Test for Alzheimer's Disease | July 2022 | May 2025 | Allow | 34 | 2 | 0 | No | No |
| 17808423 | Vascular Extracellular Matrix Hydrogel | June 2022 | September 2024 | Allow | 27 | 1 | 0 | Yes | No |
| 17618104 | FPR2 RECEPTOR AGONIST APTAMERS AND USES THEREOF | June 2022 | December 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17784093 | GENE THERAPY OF HEMOPHILIA A USING VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION | June 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17737052 | USE OF VETO CELLS FOR THE TREATMENT OF SICKLE CELL DISEASE | May 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17774140 | METHODS OF MODULATING HAIR FOLLICLE STEM CELL QUIESCENCE BY MODULATING DERMAL NICHE ACTIVATOR GAS6 | May 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17732478 | USE OF HISTONE DEUBIQUITINASE IN PREPARING DRUG FOR PREVENTING AGING AND TREATING AGING-RELATED DISEASES | April 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17726833 | COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17659157 | CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES | April 2022 | August 2024 | Allow | 28 | 2 | 0 | No | No |
| 17658446 | CELL CULTURE BASE MATERIAL AND CELL CULTURE BASE MATERIAL WITH CELLS | April 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17702586 | Irradiation of Red Blood Cells and Anaerobic Storage | March 2022 | May 2024 | Allow | 26 | 1 | 0 | No | No |
| 17762690 | COMPOSITIONS AND METHODS FOR TREATMENT OF LIQUID CANCERS | March 2022 | October 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17642140 | USE OF GHOST NANOVESICLES AS THERAPEUTICS | March 2022 | November 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17691028 | STEM CELL COMPOSITION | March 2022 | March 2025 | Abandon | 37 | 2 | 1 | No | No |
| 17677163 | CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS | February 2022 | September 2022 | Allow | 7 | 2 | 0 | Yes | No |
| 17636317 | OLIGONUCLEOTIDE-BASED THERAPY FOR ULCERATIVE COLITIS | February 2022 | November 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17581329 | NOVEL ANUCLEATED CELLS AND USES THEREOF | January 2022 | June 2024 | Abandon | 28 | 4 | 0 | Yes | No |
| 17571116 | CELL THERAPEUTIC AGENT FOR ANTI-INFLAMMATORY OR DAMAGED TISSUE REGENERATION COMPRISING PRUSSIAN BLUE NANOPARTICLES, AND METHOD FOR PREPARING THE SAME | January 2022 | September 2025 | Abandon | 44 | 4 | 1 | No | No |
| 17556380 | MAPC TREATMENT OF BRAIN INJURIES AND DISEASES | December 2021 | June 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17556330 | MAPC TREATMENT OF BRAIN INJURIES AND DISEASES | December 2021 | January 2025 | Abandon | 37 | 2 | 0 | No | No |
| 17594707 | PIM1 INHIBITORS FOR USE IN TREATMENT OF VIRAL INFECTION AND PHARMACEUTICAL COMPOSITIONS THEREOF | October 2021 | March 2025 | Allow | 41 | 1 | 0 | No | No |
| 17510717 | OPTIMIZED METHOD FOR LARGE SCALE PRODUCTION OF PARVOVIRUS H-1 IN AN ESSENTIALLY SERUM-FREE MEDIUM | October 2021 | February 2025 | Abandon | 40 | 2 | 0 | Yes | No |
| 17594661 | METHODS AND COMPOSITIONS FOR REPROGRAMMING MÜLLER GLIA | October 2021 | July 2025 | Allow | 45 | 1 | 1 | No | No |
| 17606410 | COMPOSITIONS USEFUL FOR TREATMENT OF POMPE DISEASE | October 2021 | November 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17605719 | COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF CARBAZOLE | October 2021 | January 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17503756 | METHOD FOR REPAIRING DAMAGED TISSUE | October 2021 | April 2025 | Abandon | 42 | 3 | 0 | No | No |
| 17500341 | BONE-LIKE PROSTHETIC IMPLANTS | October 2021 | April 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17602922 | METHODS FOR PRODUCING REGULATORY B CELLS AND USES THEREOF | October 2021 | September 2025 | Allow | 47 | 2 | 0 | No | No |
| 17469553 | CRYOPRESERVATION METHOD | September 2021 | September 2024 | Abandon | 37 | 1 | 1 | No | No |
| 17436640 | IMMUNOMODULATING MESENCHYMAL STEM CELLS | September 2021 | June 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17467358 | LIVE CELL CONSTRUCTS FOR PRODUCTION OF CULTURED MILK PRODUCT AND METHODS USING THE SAME | September 2021 | February 2025 | Abandon | 41 | 4 | 0 | Yes | Yes |
| 17434488 | AMNIOTIC FLUID-DERIVED EXTRACELLULAR VESICLES AND USES THEREOF FOR WOUND HEALING | August 2021 | August 2025 | Allow | 47 | 3 | 1 | Yes | No |
| 17432758 | METHOD OF HOMING AND RETENTION OF GAMMADELTA T CELLS, OPTIONALLY WITH NATURAL KILLER CELLS, FOR GENERATING CELL COMPOSITIONS FOR USE IN THERAPY | August 2021 | October 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17432011 | Compositions Comprising Microbial Polypeptides for Degrading Glycogen and Methods for the Treatment of Glycogen Storage Diseases | August 2021 | December 2025 | Allow | 52 | 2 | 1 | No | No |
| 17430055 | COMPOSITIONS AND METHODS FOR ENHANCED LYMPHOCYTE-MEDIATED IMMUNOTHERAPY | August 2021 | November 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17427393 | OLIGONUCLEOTIDE MOLECULE AND APPLICATION THEREOF IN TUMOR THERAPY | July 2021 | May 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17381192 | METHOD FOR EX VIVO EXPANSION OF REGULATORY T CELLS | July 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17423236 | A METHOD OF GENE EDITING | July 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17373089 | IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOF | July 2021 | December 2024 | Abandon | 41 | 2 | 0 | No | No |
| 17363154 | METHOD OF PREPARING MESENCHYMAL-LIKE STEM CELLS AND MESENCHYMAL-LIKE STEM CELLS PREPARED THEREBY | June 2021 | March 2024 | Abandon | 32 | 6 | 0 | Yes | No |
| 17419239 | CAR T CELL METHODS AND CONSTRUCTS | June 2021 | June 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17413392 | ANELLOSOMES AND METHODS OF USE | June 2021 | January 2026 | Allow | 55 | 2 | 1 | No | No |
| 17344205 | MAPC TREATMENT OF BRAIN INJURIES AND DISEASES | June 2021 | April 2024 | Allow | 34 | 1 | 0 | No | No |
| 17339440 | ENHANCED STEM CELL COMPOSITION | June 2021 | March 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17319760 | VIABLE BIOENGINEERED SKIN CONSTRUCTS | May 2021 | May 2024 | Abandon | 36 | 2 | 0 | No | No |
| 17302855 | METHODS AND COMPOSITIONS FOR TREATMENT OF BONE DEFECTS WITH PLACENTAL CELL POPULATIONS | May 2021 | March 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17291936 | T Cells with Improved Mitochondrial Function | May 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17242575 | FORMULATIONS AND METHODS FOR ACTIVATING SIGNALING MOLECULES OUTSIDE A NATIVE PHYSIOLOGICAL RESPONSE | April 2021 | December 2023 | Abandon | 31 | 1 | 1 | No | No |
| 17243173 | siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF | April 2021 | October 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17238760 | NEURAL CELL EXTRACELLULAR VESICLES | April 2021 | June 2024 | Allow | 38 | 5 | 0 | Yes | Yes |
| 17233783 | METHOD FOR CULTURING A SUBPOPULATION OF CIRCULATING EPITHELIAL TUMOUR CELLS FROM A BODY FLUID | April 2021 | October 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17284212 | USES OF MODIFIED RNA ENCODING RETINALDEHYDE DEHYDROGENASE | April 2021 | August 2025 | Abandon | 52 | 2 | 1 | Yes | No |
| 17226769 | IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOF | April 2021 | June 2024 | Abandon | 39 | 2 | 0 | No | No |
| 17217065 | HUMAN UMBILICAL CORD BLOOD MESENCHYMAL STEM CELL TRANSFUSION IMMUNOTHERAPY FOR TREATMENT OF CYTOKINE STORM ASSOCIATED WITH CORONAVIRUS INFECTION | March 2021 | July 2024 | Abandon | 39 | 3 | 1 | No | No |
| 17212480 | Engineered Renal Tissues, Arrays Thereof, and Methods of Making the Same | March 2021 | August 2023 | Allow | 29 | 1 | 0 | No | No |
| 17207401 | MITOCHONDRIAL AUGMENTATION THERAPY OF RENAL DISEASES | March 2021 | November 2024 | Abandon | 44 | 8 | 0 | Yes | No |
| 17275057 | POLYNUCLEOTIDES ENCODING URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1 FOR THE TREATMENT OF CRIGLER-NAJJAR SYNDROME | March 2021 | April 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17191526 | CARDIAC STEM CELLS FOR CARDIAC REPAIR | March 2021 | January 2023 | Allow | 23 | 4 | 0 | Yes | No |
| 17147167 | IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOF | January 2021 | October 2024 | Abandon | 46 | 2 | 0 | No | Yes |
| 16950751 | METHODS OF REPROGRAMMING SOMATIC CELLS AND MATERIALS RELATED THERETO | November 2020 | March 2025 | Abandon | 52 | 3 | 1 | No | No |
| 17053597 | CAR-T CELLS EXPRESSING AN INHIBITORY ANTI-TGF-BETA-RECEPTOR II SINGLE DOMAIN ANTIBODY | November 2020 | April 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17065364 | METHODS AND COMPOSITIONS FOR HEMATOPOIETIC STEM CELL MOBILIZATION | October 2020 | April 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 17044045 | MATERIALS AND METHODS FOR THE TREATMENT OF LEWY BODY DISORDERS | September 2020 | January 2026 | Allow | 60 | 4 | 1 | No | No |
| 17006257 | ISOLATION, CULTIVATION AND USES OF STEM/PROGENITOR CELLS | August 2020 | March 2024 | Abandon | 43 | 3 | 0 | No | No |
| 16996924 | Cellular pharmaceutical product containing quantified doubling level stem cells and a method for producing it | August 2020 | March 2023 | Abandon | 31 | 1 | 0 | No | No |
| 16969558 | ALLOGENEIC COMPOSITION | August 2020 | April 2025 | Abandon | 56 | 4 | 1 | Yes | No |
| 16991902 | STEM CELL PREPARATION RESISTING HYPOXIA INJURY, PREPARATION METHOD THEREFOR, AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING ACUTE MYOCARDIAL INFARCTION | August 2020 | July 2024 | Abandon | 47 | 2 | 1 | Yes | No |
| 16963974 | DEVICE AND METHOD FOR FREEZE DRYING BIOLOGICAL SAMPLES | July 2020 | March 2024 | Abandon | 44 | 0 | 1 | No | No |
| 16931003 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | July 2020 | April 2024 | Allow | 45 | 2 | 1 | Yes | No |
| 16918979 | MESENCHYMAL STEM CELLS OR STROMAL CELLS HARBORING MODIFIED RNAS ENCODING VEGF AND BMP POLYPEPTIDES | July 2020 | March 2023 | Abandon | 33 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KIM, TAEYOON.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KIM, TAEYOON works in Art Unit 1631 and has examined 162 patent applications in our dataset. With an allowance rate of 55.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner KIM, TAEYOON's allowance rate of 55.6% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KIM, TAEYOON receive 2.94 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by KIM, TAEYOON is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +42.0% benefit to allowance rate for applications examined by KIM, TAEYOON. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.7% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 33.7% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 55.6% of appeals filed. This is in the 27% percentile among all examiners. Of these withdrawals, 40.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 107.8% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 8.6% of allowed cases (in the 92% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.